The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.
Good news! Hopstem has been awarded as one of the "Top 10 Organoid Enterprises with the Most Investment Value"!
Hopstem has honored to list on the “2023 Top 100 Future Healthcare List”
Hopstem won the "2022 Drug Innovation CHIP Seed TOP 10"
Neurophth Therapeutics and Hopstem Biotechnology Announce Strategic Partnership
The 6th Dongsheng Cup International Entrepreneurship Competition
Hopstem Biotechnology at the World Preclinical Congress - iPS Cells for Disease Modeling and Drug Discovery
Join the leader of iPSC Cell Therapy！